ORPHA:391665
Homozygous familial hypercholesterolemia
Also known as: HoFH
Publications
2,600
94.9th percentile
Trials
51
Interventional, condition-specific
Researchers
1,036
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare disorder of lipid metabolism characterized by severely elevated plasma total cholesterol, low-density lipoprotein (LDL) cholesterol levels, and subsequent premature formation of atherosclerotic plaques in the coronary arteries, proximal aorta, and other arteries, significantly increasing the risk of premature cardiovascular disease and death. Xanthomas of the skin and in tendons are also a hallmark of the disease. Lethality is high due to early complications, in particular myocardial infarction and aortic valvular disease.
How rare: 1-9 / 1 000 000 — roughly one to nine people per million. In a city the size of Kolkata, perhaps a few dozen.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0018328
- MeSH:D000090542
- UMLS:C0342881
Additional Mondo synonyms (1)
homozygous familial hypercholesterolemia
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
2,600 matched papers (1,630 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
51 matched on ClinicalTrials.gov (10 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
2,600
2,600 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
2,600 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
1,630 in the last 10 years · medium confidence · 94.9th percentile (publications denominator)
Phrase hits: 2,600 · MeSH hits: 70
Who's working on it?
1,036
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Raal FJ15 papers · 2026
Division of Endocrinology, Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Papers in Europe PMC - 02Gaudet D12 papers · 2026
Clinical Lipidology and Rare Lipid Disorders Unit, Department of Medicine, Université de Montréal Community Gene Medicine Center, Lipid Clinic Chicoutimi Hospital and ECOGENE-21 Clinical and Translational Research Center, Chicoutimi, Quebec, Canada.
Papers in Europe PMC - 03Wiegman A11 papers · 2026
Department of Paediatrics, Amsterdam UMC, Location AMC, the Netherlands (A.W.).
Papers in Europe PMC - 04Hegele RA10 papers · 2026
Departments of Medicine and Biochemistry, Schulich School of, Medicine and Robarts Research Institute, Western University, London, ON, Canada (Dr Hegele).
Papers in Europe PMC - 05
- 06Blom DJ8 papers · 2026
1Department of Medicine and Cape Heart Institute, University of Cape Town, Cape Town, South Africa.
Papers in Europe PMC - 07Reeskamp LF7 papers · 2026
Department of Vascular Medicine, University of Amsterdam, Amsterdam, The Netherlands.
Papers in Europe PMC - 08Rosenson RS7 papers · 2026
Metabolism and Lipids Program, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: robert.rosenson@mssm.edu.
Papers in Europe PMC - 09Cuchel M6 papers · 2026
Perelman School of Medicine, University of Pennsylvania, US.
Papers in Europe PMC - 10Harada-Shiba M6 papers · 2026
Cardiovascular Center, Osaka Medical & Pharmaceutical University, Osaka, 569-8686, Japan.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
51
interventional trials for this specific condition
51 interventional trials matched this specific condition name; 10 currently recruiting in our sample. 123 trials are registered for familial hypercholesterolemia, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
51 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 97.1th percentile).
medium confidence · 97.1th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
51 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT07133815·NOT YET RECRUITING·Evaluate the Long-term Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia
Conditions: Homozygous Familial Hypercholesterolemia·Matched via name + MeSH
- NCT05682378·RECRUITING·Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies
Conditions: Heterozygous or Homozygous Familial Hypercholesterolemia·Matched via name + MeSH
- NCT06125847·RECRUITING·NGGT006 Gene Therapy for Homozygous Familial Hypercholesterolemia
Conditions: Homozygous Familial Hypercholesterolemia·Matched via name + MeSH
- NCT07489209·RECRUITING·A Dose-exploration Study of EDP167 in HoFH
Conditions: Homozygous Familial Hypercholesterolemia (HoFH)·Matched via name + MeSH
- NCT07473843·NOT YET RECRUITING·Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia
Conditions: Homozygous Familial Hypercholesterolemia·Matched via name + MeSH
- NCT07491172·RECRUITING·A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
Conditions: Cardiovascular · Metabolic Disease · Dyslipidemias · Lipid Disorder·Matched via name + MeSH
- NCT07470723·RECRUITING·The ORIGIN-FH Study
Conditions: Heterozygous Familial Hypercholesterolemia (HeFH) · Homozygous Familial Hypercholesterolemia (HoFH) · Familial Hypercholesterolemia·Matched via name + MeSH
- NCT06597006·RECRUITING·Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia
Conditions: Familial Hypercholesterolemia - Homozygous·Matched via name + MeSH
- NCT07037771·RECRUITING·A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)
Conditions: Homozygous Familial Hypercholesterolemia·Matched via name + MeSH
- NCT07591298·NOT YET RECRUITING·Phase II Clinical Trial to Evaluate the Efficacy and Safety of SYH2070 Injection in Participants With Homozygous Familial Hypercholesterolemia
Conditions: Diagnosed With HoFH·Matched via name + MeSH
Broader category: familial hypercholesterolemia
123
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT06597019·RECRUITING·Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia
Conditions: Familial Hypercholesterolemia - Heterozygous·Matched via name phrase
- NCT07421284·NOT YET RECRUITING·A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia on a Background of Lipid-lowering Therapy
Conditions: Non-familial Hypercholesterolemia and Mixed Hyperlipidemia·Matched via name phrase
- NCT06833944·NOT YET RECRUITING·High Intensity Interval Training in the Treatment of Familial Hypercholesterolemia (UPPA-FH)
Conditions: Familiar Hypercholesterolemia·Matched via name phrase
- NCT05043181·NOT YET RECRUITING·Exosome-based Nanoplatform for Ldlr mRNA Delivery in FH
Conditions: Familial Hypercholesterolemia·Matched via name phrase
- NCT07421297·RECRUITING·A Study to Evaluate the Safety, Efficacy of SYH2053 as Monotherapy in Chinese Participants With Non-familial Hypercholesterolemia or Mixed Hyperlipidemia
Conditions: Non-familial Hypercholesterolemia and Mixed Hyperlipidemia·Matched via name phrase
- NCT05750667·ENROLLING BY INVITATION·Penn Family Screening for Familial Hypercholesterolemia
Conditions: Familial Hypercholesterolemia·Matched via name phrase
- NCT06439654·RECRUITING·Atlantic Lipid Lowering Treatment Optimization Program
Conditions: Familial Hypercholesterolemia · Lipoprotein Types--Lp System Lp(A) Hyperlipoproteinemia · Apolipoprotein B 100, Familial Defective · High Density Lipoprotein Deficiency·Matched via name phrase
- NCT05746247·ENROLLING BY INVITATION·Improving Diagnosis and Clinical Management of Familial Hypercholesterolemia Through Integrated Machine Learning, Implementation Science, and Behavioral Economics
Conditions: Familial Hypercholesterolemia·Matched via name phrase
- NCT07465263·RECRUITING·A Study to Evaluate the SYH2053 Injection in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)
Conditions: Heterozygous Familial Hypercholesterolemia (HeFH)·Matched via name phrase
- NCT07614958·RECRUITING·Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial Hypercholesterolemia or Mixed Dyslipidemia at High to Very High Cardiovascular Risk, During a Treatment Period of Approximately 84 Days
Conditions: Mixed Dyslipidemia · Hypercholesterolaemia·Matched via name phrase
- NCT03989167·RECRUITING·Clinical Decision Support for Familial Hypercholesterolemia
Conditions: Hypercholesterolemia, Familial · Clinical Decision Support·Matched via name phrase
- NCT05348564·RECRUITING·Comparing Direct vs Indirect Methods for Cascade Screening
Conditions: Long QT Syndrome · Familial Hypercholesterolemia · Ethics · Genetic Testing·Matched via name phrase
- NCT06293729·NOT YET RECRUITING·Safety and Efficacy Study of NGGT006 in Refractory Hypercholesterolemia Patients
Conditions: Refractory Hypercholesterolemia · Familial Hypercholesterolemia·Matched via name phrase
- NCT06568471·RECRUITING·A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia
Conditions: Hypercholesterolemia · Dyslipidemias · Primary Hypercholesterolemia · Heterozygous Familial Hypercholesterolemia·Matched via name phrase
- NCT07353398·NOT YET RECRUITING·Early-phase Study of ART002g1 Injection in HeFH: Safety, Tolerability and Preliminary Efficacy
Conditions: Heterozygous Familial Hypercholesterolemia·Matched via name phrase
Observational and natural-history studies
14 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT01109368·RECRUITING·The Rogosin Institute Homozygous Familial Hypercholesterolemia Repository
Conditions: Homozygous Familial Hypercholesterolemia·Matched via name + MeSH
- NCT07447648·RECRUITING·Assessing the Impact of Intensification of Lipid Lowering Therapy With Guidelines-based Evinacumab Administration on Coronary Plaque Volumes Measured by Coronary Computed Tomography Angiography (CCTA) in Patients With Homozygous Familial Hypercholesterolemia (HoFH)
Conditions: Homozygous Familial Hypercholesterolemia (HoFH) · Coronary Computed Tomography Angiography·Matched via name + MeSH
- NCT04815005·RECRUITING·HoFH, the International Clinical Collaborators Registry
Conditions: Homozygous Familial Hypercholesterolemia·Matched via name + MeSH
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26Directly listed under NPRD Group 1.
Group 1 — one-time curative treatment
Up to ₹50 lakh per patient
Financial support for treatment at notified Centres of Excellence (figures evolved from the original ₹20 lakh Group-1 ceiling).
Policy figures change. Verify current MoHFW / CoE guidance before relying on any amount. Verify
Centres of Excellence (15)
- All India Institute of Medical Sciences (AIIMS) — New Delhi, Delhi
- Maulana Azad Medical College — New Delhi, Delhi
- Sanjay Gandhi Post Graduate Institute of Medical Sciences — Lucknow, Uttar Pradesh
- Post Graduate Institute of Medical Education and Research (PGIMER) — Chandigarh, Chandigarh
- Centre for DNA Fingerprinting & Diagnostics with Nizam’s Institute of Medical Sciences — Hyderabad, Telangana
- King Edward Memorial Hospital — Mumbai, Maharashtra
- Institute of Post-Graduate Medical Education and Research (IPGMER) — Kolkata, West Bengal
- Centre for Human Genetics with Indira Gandhi Hospital — Bengaluru, Karnataka
- Institute of Child Health and Hospital for Children (ICH & HC) — Chennai, Tamil Nadu
- All India Institute of Medical Sciences (AIIMS) — Jodhpur, Rajasthan
- Sree Avittam Thirunal Hospital (SAT), Government Medical College — Thiruvananthapuram, Kerala
- All India Institute of Medical Sciences (AIIMS) — Bhopal, Madhya Pradesh
- Regional Institute of Medical Sciences (RIMS) — Imphal, Manipur
- All India Institute of Medical Sciences (AIIMS) — Patna, Bihar
- Assam Medical College & Hospital — Dibrugarh, Assam
Voluntary contributions / crowdfunding (separate from CoE funding): https://rarediseases.mohfw.gov.in/
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Homozygous familial hypercholesterolemia"
MeSH descriptor terms unioned into the query: Homozygous Familial Hypercholesterolemia
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Homozygous familial hypercholesterolemia"
Interventional trials matched via: both (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 51 interventional · 14 observational · 1 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"familial hypercholesterolemia"
Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: HoFH
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T15:09:31.397Z
